MYGN
Myriad Genetics Inc Health Care In Vitro & In Vivo Diagnostic Substances Russell 3000
$6.35Close
$593.7MMarket cap
$2.87 – $6.6752-week range
Nov 4, 2026Next report · after the close
Highlights
Strengths
- Accumulation up-day volume 2.9× down-day volume over 50 sessions
Cautions
- Extended 8.8 ATR above its 50-day average
- Results soon Nov 4, 2026, in 3 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
5%
1wk
up 9.1%
price change
1mo
up 47.3%
price change
12-month return
up 100%
total, dividends included
F-score
5 / 9
Mixed
Altman Z
-1.48
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
1.6×
price / book
Earnings yield
down 68.6%
EBIT / enterprise value
Cheaper than
35%
of the market · expensive
Revenue growth
down 2%
year on year
EPS growth
—
latest quarter
Sales growth
down 11%
latest quarter · -13 pts
ROE
down 68%
return on equity
Free cash margin
0%
$1.8M FCF
D/E
0.33
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Piotroski tests
- not yet profitable on its assets
- profitability slipped from last year
- took on more long-term debt
- issued more shares
- generating cash from operations
- profits backed by cash
- short-term liquidity improved
- gross margin widened
- assets working harder
Repair signals
- FCF turned positive ($-9M → $2M)
Trade setup
ATR%
5.8%
$0.37 a day · 2×ATR $5.62
RS
—
vs the universe
Trend
—
trend template
Relative volume
0.6×
vs 50-day average
Up/down volume
2.88
50 sessions
Implied move
—
no option chain · report Nov 4, 2026
Screen verdict
Did not qualify for any screen.
Warning signs
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Shareholders diluted The share count rose 2.4% over the year, from 91m to 94m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
- Revenue shrinking Revenue fell 1.6% over the year, from $837.6M to $824.5M.
Last reported
Jul 30, 2026
Financials
- Gross 70%
- Net -44%
- Free cash 0%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $557.1M | $690.6M | $678.4M | $753.2M | $837.6M | $824.5M |
| Gross margin | — | — | 70% | 69% | 70% | 70% |
| Operating income | -$289.7M | -$190.5M | -$140.6M | -$257.4M | -$123.5M | -$387.2M |
| Net income | -$223.6M | -$27.0M | -$112.0M | -$263.0M | -$127.0M | -$366.0M |
| Net margin | -40% | -4% | -17% | -35% | -15% | -44% |
| Earnings per share | -$2.99 | -$0.35 | -$1.39 | -$3.18 | -$1.40 | -$3.95 |
| Free cash flow | — | $600,000 | -$151.6M | -$110.9M | -$8.7M | $1.8M |
| Free cash margin | — | 0% | -22% | -15% | -1% | 0% |
| Cash | $117.0M | $257.4M | $56.9M | $132.1M | $102.4M | $149.6M |
| Long-term debt | $224.8M | $0 | $0 | $38.5M | $39.6M | $119.9M |
| Shareholders' equity | $881.0M | $967.8M | $885.8M | $783.2M | $701.1M | $368.0M |
| Shares outstanding | 75.40m | 80m | 81.20m | 89.90m | 91.30m | 93.50m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Jul 31, 2026 | Quarterly ↗ | Jun 30, 2026 | 31d |
| May 6, 2026 | Quarterly ↗ | Mar 31, 2026 | 36d |
| Feb 24, 2026 | Annual ↗ | Dec 31, 2025 | 55d |
| Nov 4, 2025 | Quarterly ↗ | Sep 30, 2025 | 35d |
| Aug 6, 2025 | Quarterly ↗ | Jun 30, 2025 | 37d |
| May 7, 2025 | Quarterly ↗ | Mar 31, 2025 | 37d |
| Feb 28, 2025 | Annual ↗ | Dec 31, 2024 | 59d |
| Nov 8, 2024 | Quarterly ↗ | Sep 30, 2024 | 39d |
| Aug 7, 2024 | Quarterly ↗ | Jun 30, 2024 | 38d |
| May 8, 2024 | Quarterly ↗ | Mar 31, 2024 | 38d |
| Feb 28, 2024 | Annual ↗ | Dec 31, 2023 | 59d |
| Nov 7, 2023 | Quarterly ↗ | Sep 30, 2023 | 38d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 20, 2026 | Material agreement · Regulation FD ↗ |
| Oct 9, 2026 | Director or officer change ↗ |
| Sep 16, 2026 | Director or officer change · Regulation FD ↗ |
| Jul 30, 2026 | Results ↗ |
| Jun 23, 2026 | Director or officer change ↗ |
| Jun 4, 2026 | Director or officer change · Shareholder vote ↗ |
| May 5, 2026 | Results ↗ |
| Feb 23, 2026 | Results ↗ |
| Jan 12, 2026 | Results ↗ |
| Nov 3, 2025 | Results ↗ |
| Oct 7, 2025 | Director or officer change ↗ |
| Oct 3, 2025 | Director or officer change ↗ |